Veterans Health Administration

The American Society of Nephrology has called upon Congress to increase funding for veterans living with kidney diseases, according to the press release.

The Veterans’ Health Administration will provide coverage of a drug for the treatment of Alzheimer’s disease to veterans with early stages of the disease, according to a press release from the drug’s manufacturer.

WASHINGTON — The Veterans Health Administration is providing interprofessional training to health care providers to improve the quality of primary care in the U.S., according to a speaker at the Primary Care Collaborative annual meeting.

PHILADELPHIA — The initiation of disease-modifying antirheumatic drugs among U.S. veterans with active rheumatoid arthritis requires improvement, regardless of rural or urban setting, according to a presentation at ACR Convergence 2022.

CHICAGO — Among older veterans with hypertension, there was no difference in the incidence of major adverse CV events after treatment with hydrochlorothiazide compared with chlorthalidone, according to new research.

CHICAGO — With more than 1.5 million veterans diagnosed with headache over the past two decades, the Veterans Health Administration must improve outreach and care to address disparities, an expert said at ANA 2022.

Headache disorders in American veterans were higher for men than women in incidence related to trauma, but men had fewer encounters for headaches and fewer visits to headache specialists, according to a study published in Neurology.

Diagnoses of psychiatric disorders were associated with increased incidence of COVID-19 breakthrough infection in VA patients, with the strongest associations found in older patients, according to a study published in JAMA Network Open.

Individuals whose underlying poor health may make them less likely to benefit from lung cancer screening appeared more likely to undergo the scans than those with better health status, according to study results in JAMA Network Open.

Benzodiazepine prescriptions for U.S. military veterans with PTSD declined due to decreased prevalence over a 10-year period, according to a retrospective observational study published in the Journal of Clinical Psychiatry.